Upregulation of SIRT2 in NSCLC cells increases the sensitivity to cisplatin treatment while SIRT3 promotion reduces cisplatin resistance in LC by modulating the FoxO3/Cdc10-dependent transcript 1 protein axis.253,427 In relation to LC radioresistance, SIRT3 promotes DNA damage repair and radioresistance through ataxia telangiectasia mutated–Chk2 in NSCLC cells.428 SIRTs can affect radioresistance in LC through the regulation of tumor metabolism. The gene discussed is SIRT3; the disease is non-small cell lung carcinoma.